Is HCW Biologics Inc. Common Stock a good investment? HCW Biologics Inc. Common Stock (HCWB) is currently trading at 3.34 USD.
Earnings Schedule: HCW Biologics Inc. Common Stock is expected to release its next earnings report on Aug. 7, 2026. The market consensus estimate for Forward EPS is -0.55.
No, it does not currently pay a dividend.
HCW Biologics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Aug. 7, 2026. The company currently has a trailing EPS of -49.74.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| April 11, 2025 | 0.030000 |
| June 30, 2026 | 0.170000 |
Community Discussion